Cardiology

Breast Cancer, Non-metastatic

Questions discussed in this category

Which regimen would you recommend for a young patient with node-positive, triple-positive breast cancer with significant anthracycline-induced cardiomyopathy?

Question inspired by the case of a young woman with LVEF 20-25%, asymptomatic.

1 Answer available

How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?

Such as breast plans with < 200 cGy mean heart dose

1 Answer available

How would you treat an elderly patient with borderline cardiac dysfunction who has stage 3 HR+ HER2- breast cancer?

2 Answers available

Papers discussed in this category

Annals of Oncology, 2021 Sep 29

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

JAMA oncology, 2024 Feb 01

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.

Related Topics in Cardiology